Why LeonaBio, Inc.’s (LONA) Stock Is Down 5.01%
As of Monday, July 27, LeonaBio, Inc.’s LONA share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Commentary & Analysis
Why LeonaBio, Inc.’s (LONA) Stock Is Up 5.66%
As of Friday, July 24, LeonaBio, Inc.’s LONA share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Why LeonaBio, Inc.’s (LONA) Stock Is Down 9.47%
As of Monday, July 06, LeonaBio, Inc.’s LONA share price has dipped by 9.47%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why LeonaBio, Inc.’s (LONA) Stock Is Down 5.35%
As of Wednesday, July 01, LeonaBio, Inc.’s LONA share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Jenna Brashear
Why LeonaBio, Inc.’s (LONA) Stock Is Up 6.43%
As of Tuesday, June 30, LeonaBio, Inc.’s LONA share price has surged by 6.43%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | LONA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $73.9 | $634.5 | 19% |
|
| Shares Out (Mil) | 19.0 | 44.5 | 30% |
|
| Institutional Ownership | 85.7% | 84.4% | 54% |
|
| Float (Mil) | 5.6 | 46.8 | 13% |
|
| Beta | 2.02 | 0.73 | 92% |
|
| Avg Daily Volume (000s) | 11 | 365 | 17% |
|
| Price Change (52-week) |
104.5% | 66.1% | 91% |
|
| Growth | LONA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (39.5%) | (1.4%) | 9% |
|
| EPS (5yr) | (8.2%) | 14.9% | 23 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (37.0%) | (14.9%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LONA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $276 | na |
|
| Net Income (TTM) (Mil) | ($129) | ($11) | 9% |
|
| EPS (TTM) | ($16.063) | ($0.700) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $7 | $309 | 7% |
|
| Valuation | LONA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.50 | 2.88 | 38% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LONA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (224.9%) | (22.5%) | 2% |
|
| ROE | (298.8%) | (19.8%) | 3% |
|
| Liabilities to Assets | 31.1% | 32.4% | 22% |
|
| F-Score | 3 | 3 | 18% |
|
LeonaBio, Inc. did not pass any screens on 8/13/2026.
